Seegene Inc - Asset Resilience Ratio
Seegene Inc (096530) has an Asset Resilience Ratio of 28.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Seegene Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Seegene Inc's Asset Resilience Ratio has changed over time. See Seegene Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Seegene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Seegene Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩342.92 Billion | 28.16% |
| Total Liquid Assets | ₩342.92 Billion | 28.16% |
Asset Resilience Insights
- Very High Liquidity: Seegene Inc maintains exceptional liquid asset reserves at 28.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Seegene Inc Industry Peers by Asset Resilience Ratio
Compare Seegene Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Seegene Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Seegene Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.81% | ₩262.92 Billion ≈ $178.17 Million |
₩1.21 Trillion ≈ $816.80 Million |
-4.60pp |
| 2023-12-31 | 26.41% | ₩330.50 Billion ≈ $223.98 Million |
₩1.25 Trillion ≈ $848.09 Million |
-17.00pp |
| 2022-12-31 | 43.41% | ₩603.78 Billion ≈ $409.17 Million |
₩1.39 Trillion ≈ $942.51 Million |
+11.63pp |
| 2021-12-31 | 31.78% | ₩473.45 Billion ≈ $320.85 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.43pp |
| 2020-12-31 | 29.35% | ₩321.26 Billion ≈ $217.71 Million |
₩1.09 Trillion ≈ $741.78 Million |
+1.75pp |
| 2019-12-31 | 27.60% | ₩54.01 Billion ≈ $36.60 Million |
₩195.72 Billion ≈ $132.63 Million |
+4.73pp |
| 2018-12-31 | 22.87% | ₩37.46 Billion ≈ $25.39 Million |
₩163.81 Billion ≈ $111.01 Million |
+0.02pp |
| 2017-12-31 | 22.85% | ₩37.66 Billion ≈ $25.52 Million |
₩164.84 Billion ≈ $111.71 Million |
-12.70pp |
| 2016-12-31 | 35.55% | ₩73.80 Billion ≈ $50.01 Million |
₩207.62 Billion ≈ $140.70 Million |
+22.05pp |
| 2015-12-31 | 13.50% | ₩26.19 Billion ≈ $17.75 Million |
₩194.05 Billion ≈ $131.50 Million |
+5.12pp |
| 2014-12-31 | 8.38% | ₩11.60 Billion ≈ $7.86 Million |
₩138.45 Billion ≈ $93.83 Million |
+1.40pp |
| 2013-12-31 | 6.97% | ₩9.00 Billion ≈ $6.10 Million |
₩129.04 Billion ≈ $87.45 Million |
-2.75pp |
| 2012-12-31 | 9.73% | ₩8.13 Billion ≈ $5.51 Million |
₩83.62 Billion ≈ $56.67 Million |
-- |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more